{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:13:09Z","timestamp":1782951189016,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"DOI":"10.1007\/s00392-025-02831-0","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:04:56Z","timestamp":1766052296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular effects of mineralocorticoid receptor antagonists in acute coronary syndrome: an updated systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8433-8329","authenticated-orcid":false,"given":"Luis Rene","family":"Puglla Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0539-6764","authenticated-orcid":false,"given":"Anthony David","family":"Rojas Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-5417","authenticated-orcid":false,"given":"Pawe\u0142","family":"\u0141ajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ramon","family":"Ruiz Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2831_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40256-016-0185-0","volume":"16","author":"CA D\u00e9zsi","year":"2016","unstructured":"D\u00e9zsi CA, Szentes V (2016) Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on prothrombotic processes and myocardial infarction risk. Am J Cardiovasc Drugs 16:399\u2013406. https:\/\/doi.org\/10.1007\/s40256-016-0185-0","journal-title":"Am J Cardiovasc Drugs"},{"key":"2831_CR2","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ahj.2008.12.013","volume":"157","author":"F Beygui","year":"2009","unstructured":"Beygui F, Montalescot G, Vicaut E et al (2009) Aldosterone and long-term outcome after myocardial infarction: a substudy of the OPERA study. Am Heart J 157:680\u2013687.e2. https:\/\/doi.org\/10.1016\/j.ahj.2008.12.013","journal-title":"Am Heart J"},{"key":"2831_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJM199909023411009","volume":"341","author":"KT Weber","year":"1999","unstructured":"Weber KT (1999) Aldosterone and spironolactone in heart failure. N Engl J Med 341:753\u2013755. https:\/\/doi.org\/10.1056\/NEJM199909023411009","journal-title":"N Engl J Med"},{"key":"2831_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"2831_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709\u2013717. https:\/\/doi.org\/10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"2831_CR6","doi-asserted-by":"publisher","first-page":"H647","DOI":"10.1152\/ajpheart.2001.281.2.H647","volume":"281","author":"JA Delyani","year":"2001","unstructured":"Delyani JA, Robinson EL, Rudolph AE (2001) Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 281:H647\u2013H654. https:\/\/doi.org\/10.1152\/ajpheart.2001.281.2.H647","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2831_CR7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321. https:\/\/doi.org\/10.1056\/NEJMoa030207","journal-title":"N Engl J Med"},{"key":"2831_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ahj.2017.09.010","volume":"195","author":"M Bossard","year":"2018","unstructured":"Bossard M, Binbraik Y, Beygui F et al (2018) Mineralocorticoid receptor antagonists in patients with acute myocardial infarction: a systematic review and meta-analysis of randomized trials. Am Heart J 195:60\u201369. https:\/\/doi.org\/10.1016\/j.ahj.2017.09.010","journal-title":"Am Heart J"},{"key":"2831_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamainternmed.2018.0850","volume":"178","author":"K Dahal","year":"2018","unstructured":"Dahal K, Hendrani A, Sharma SP et al (2018) Aldosterone antagonist therapy and mortality in patients with ST-segment elevation myocardial infarction without heart failure: a systematic review and meta-analysis. JAMA Intern Med 178:913\u2013920. https:\/\/doi.org\/10.1001\/jamainternmed.2018.0850","journal-title":"JAMA Intern Med"},{"key":"2831_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijchv.2014.03.005","volume":"3","author":"E Vizzardi","year":"2014","unstructured":"Vizzardi E, Regazzoni V, Caretta G et al (2014) Mineralocorticoid receptor antagonist in heart failure: past, present and future perspectives. Int J Cardiol Heart Vessel 3:6\u201314. https:\/\/doi.org\/10.1016\/j.ijchv.2014.03.005","journal-title":"Int J Cardiol Heart Vessel"},{"key":"2831_CR11","unstructured":"Higgins JPT, Thomas J, Chandler J et al (eds). Cochrane Handbook for Systematic Reviews of Interventions, version 6.5 (updated August 2024). Cochrane. Available from www.cochrane.org\/handbook. Accessed 18 Sept 2025"},{"key":"2831_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"2831_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan \u2014 a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"2831_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"2831_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"2831_CR16","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res 27:1785\u20131805. https:\/\/doi.org\/10.1177\/0962280216669183","journal-title":"Stat Methods Med Res"},{"key":"2831_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird N (2015) Meta-analysis in clinical trials revisited. Contemp Clin Trials 45:139\u2013145. https:\/\/doi.org\/10.1016\/j.cct.2015.09.002","journal-title":"Contemp Clin Trials"},{"key":"2831_CR18","unstructured":"R Core Team (2021) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. https:\/\/www.R-project.org\/.\u00a0Accessed 18 Sept 2025"},{"key":"2831_CR19","doi-asserted-by":"publisher","unstructured":"Jolly SS, d\u2019Entremont MA, Pitt B et al (2025) CLEAR Investigators. Routine spironolactone in acute myocardial infarction. N Engl J Med 392:643\u2013652. https:\/\/doi.org\/10.1056\/NEJMoa2405923","DOI":"10.1056\/NEJMoa2405923"},{"key":"2831_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ahj.2019.02.005","volume":"211","author":"H Bulluck","year":"2019","unstructured":"Bulluck H, Fr\u00f6hlich GM, Nicholas JM et al (2019) Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: the MINIMIZE STEMI trial. Am Heart J 211:60\u201367. https:\/\/doi.org\/10.1016\/j.ahj.2019.02.005","journal-title":"Am Heart J"},{"key":"2831_CR21","doi-asserted-by":"publisher","unstructured":"Beygui F, Cayla G, Roule V et al (2016) ALBATROSS Investigators. Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial. J Am Coll Cardiol 67:1917\u20131927. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.033","DOI":"10.1016\/j.jacc.2016.02.033"},{"key":"2831_CR22","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","volume":"35","author":"G Montalescot","year":"2014","unstructured":"Montalescot G, Pitt B, Lopez de Sa E et al (2014) REMINDER Investigators. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the REMINDER study. Eur Heart J 35:2295\u20132302. https:\/\/doi.org\/10.1093\/eurheartj\/ehu164","journal-title":"Eur Heart J"},{"key":"2831_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ahj.2009.04.001","volume":"157","author":"RA Weir","year":"2009","unstructured":"Weir RA, Mark PB, Petrie CJ et al (2009) Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 157:1088\u20131096. https:\/\/doi.org\/10.1016\/j.ahj.2009.04.001","journal-title":"Am Heart J"},{"key":"2831_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/00365510902802278","volume":"69","author":"I Uzunhasan","year":"2009","unstructured":"Uzunhasan I, Yildiz A, Coskun U et al (2009) Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction. Scand J Clin Lab Invest 69:545\u2013549. https:\/\/doi.org\/10.1080\/00365510902802278","journal-title":"Scand J Clin Lab Invest"},{"key":"2831_CR25","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0f","volume":"107","author":"M Hayashi","year":"2003","unstructured":"Hayashi M, Tsutamoto T, Wada A et al (2003) Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling. Circulation 107:2559\u20132565. https:\/\/doi.org\/10.1161\/01.CIR.0000068340.96506.0f","journal-title":"Circulation"},{"key":"2831_CR26","first-page":"121","volume":"2","author":"P Di Pasquale","year":"2001","unstructured":"Di Pasquale P, Cannizzaro S, Giubilato A et al (2001) Additional beneficial effects of canrenoate in patients with anterior myocardial infarction on ACE-inhibitor treatment. Ital Heart J 2:121\u2013129","journal-title":"Ital Heart J"},{"key":"2831_CR27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1161\/HYPERTENSIONAHA.109.140384","volume":"54","author":"CT Stier Jr","year":"2009","unstructured":"Stier CT Jr (2009) Mineralocorticoid receptors in myocardial infarction. Hypertension 54:1211\u20131212. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.140384","journal-title":"Hypertension"},{"key":"2831_CR28","doi-asserted-by":"publisher","first-page":"4F","DOI":"10.1016\/j.amjcard.2006.03.004","volume":"97","author":"JN Cohn","year":"2006","unstructured":"Cohn JN, Colucci W (2006) Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 97:4F\u201312F. https:\/\/doi.org\/10.1016\/j.amjcard.2006.03.004","journal-title":"Am J Cardiol"},{"key":"2831_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11886-020-01399-7","volume":"22","author":"JS Rico-Mesa","year":"2020","unstructured":"Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS (2020) Mineralocorticoid receptor antagonists: a comprehensive review of finerenone. Curr Cardiol Rep 22:140. https:\/\/doi.org\/10.1007\/s11886-020-01399-7","journal-title":"Curr Cardiol Rep"},{"key":"2831_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1161\/CIRCRESAHA.116.302706","volume":"116","author":"CM Ferrario","year":"2015","unstructured":"Ferrario CM, Schiffrin EL (2015) Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ Res 116:206\u2013213. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.302706","journal-title":"Circ Res"},{"key":"2831_CR31","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3390\/cells10061552","volume":"10","author":"M Guitart-Mampel","year":"2021","unstructured":"Guitart-Mampel M, Urquiza P, Borges JI et al (2021) Impact of aldosterone on the failing myocardium: insights from mitochondria and adrenergic receptor signaling and function. Cells 10:1552. https:\/\/doi.org\/10.3390\/cells10061552","journal-title":"Cells"},{"key":"2831_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1291\/hypres.30.427","volume":"30","author":"M Takeda","year":"2007","unstructured":"Takeda M, Tatsumi T, Matsunaga S et al (2007) Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11\u03b2-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res 30:427\u2013437. https:\/\/doi.org\/10.1291\/hypres.30.427","journal-title":"Hypertens Res"},{"key":"2831_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the RALES study. N Engl J Med 351:543\u2013551. https:\/\/doi.org\/10.1056\/NEJMoa040135","journal-title":"N Engl J Med"},{"key":"2831_CR34","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ et al (2023) 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 44:3720\u20133826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191","journal-title":"Eur Heart J"},{"key":"2831_CR35","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1161\/CIR.0000000000001309","volume":"151","author":"SV Rao","year":"2025","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M et al (2025) 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes. Circulation 151:e771\u2013e862. https:\/\/doi.org\/10.1161\/CIR.0000000000001309","journal-title":"Circulation"},{"key":"2831_CR36","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1002\/ehf2.15329","volume":"12","author":"J Wang","year":"2025","unstructured":"Wang J, Zheng M, Yang Y et al (2025) Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases. ESC Heart Fail 12:3062\u20133072. https:\/\/doi.org\/10.1002\/ehf2.15329","journal-title":"ESC Heart Fail"},{"key":"2831_CR37","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1111\/bph.15708","volume":"179","author":"J Bauersachs","year":"2022","unstructured":"Bauersachs J, L\u00f3pez-Andr\u00e9s N (2022) Mineralocorticoid receptor in cardiovascular diseases\u2014clinical trials and mechanistic insights. Br J Pharmacol 179:3119\u20133134. https:\/\/doi.org\/10.1111\/bph.15708","journal-title":"Br J Pharmacol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02831-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02831-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02831-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:04:57Z","timestamp":1766052297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02831-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":37,"alternative-id":["2831"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02831-0","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This meta-analysis did not require informed consent or institutional review board approval, for all data are publicly available and did not involve access to individual patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}